OXFORD ENDOVASCULAR LIMITED

Active Oxford

Research and experimental development on biotechnology

9 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
O

OXFORD ENDOVASCULAR LIMITED

Research and experimental development on biotechnology

Founded 9 Sept 2015 Active Oxford, United Kingdom 9 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 21 Jan 2026 Next due 30 Jun 2027 14 months remaining
Confirmation Submitted 1 Oct 2025 Next due 23 Sept 2026 5 months remaining
Net assets £5M £2M 2025 year on year
Total assets £6M £3M 2025 year on year
Total Liabilities £584K £210K 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

9400 Garsington Road Oxford Business Park Oxford OX4 2HN United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for OXFORD ENDOVASCULAR LIMITED (09769779), an active life sciences and medical technology company based in Oxford, United Kingdom. Incorporated 9 Sept 2015. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type Total Exemption Full
Next accounts 31 December 2026
Due by 30 September 2027 9 months

Net Assets, Total Assets & Total Liabilities (2016–2025)

Cash in Bank

£5.16M

Decreased by £2.76M (-35%)

Net Assets

£5.27M

Decreased by £2.39M (-31%)

Total Liabilities

£584.30k

Decreased by £210.41k (-26%)

Turnover

N/A

Employees

9

Increased by 3 (+50%)

Debt Ratio

10%

Increased by 1 (+11%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
Dec Year End
2024
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2
Grants 1

Investors (9)

Investor NameInvestor SinceParticipating Rounds
Investor 1Apr 2021Series A
Investor 4Apr 2021Series A
Investor 5Apr 2021Series A

Share Capital

Share Capital

Share allotments and capital structure

12 Allotments 383,526 Shares £15.68m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
2 Jan 20256,000£60£0.01
25 Apr 20243,232£133k£41.16
11 Apr 2024243£10k£41.16
9 Apr 202446,888£1.93m£41.16
3 Apr 20247,701£360k£46.77

Officers

Officers

1 active 2 resigned
Status
Martin Henry DiggleDirectorBritishSouth Africa6319 Feb 2021Active

Shareholders

Shareholders (26)

Mnl (parkwalk) Nominees Limited A/c Parkwalk
24.6%
183,253
Oxford Science Enterprises Plc
21.0%
156,303

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Parkwalk Advisors Ltd

United Kingdom

Active
Notified 9 Apr 2024
Nature of Control
  • Voting Rights 25 To 50 Percent
Ceased

Parkwalk Advisors Ltd

Ceased 8 Feb 2024

Ceased

Group Structure

Group Structure

IP GROUP PLC united kingdom
PARKWALK ADVISORS LTD united kingdom
OXFORD ENDOVASCULAR LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
21 Jan 2026AccountsAnnual accounts made up to 2025-09-30
1 Oct 2025Confirmation StatementConfirmation statement made on 2025-09-09 with updates
3 Jul 2025AccountsAnnual accounts made up to 2024-09-30
6 Jan 2025CapitalAllotment of shares (GBP 7,444.53) on 2025-01-02
4 Oct 2024OfficersTermination of Michael Karim as director on 2024-09-30
21 Jan 2026 Accounts

Annual accounts made up to 2025-09-30

1 Oct 2025 Confirmation Statement

Confirmation statement made on 2025-09-09 with updates

3 Jul 2025 Accounts

Annual accounts made up to 2024-09-30

6 Jan 2025 Capital

Allotment of shares (GBP 7,444.53) on 2025-01-02

4 Oct 2024 Officers

Termination of Michael Karim as director on 2024-09-30

Recent Activity

Latest Activity

Annual accounts made up to 2025-09-30

2 months ago on 21 Jan 2026

Confirmation statement made on 2025-09-09 with updates

6 months ago on 1 Oct 2025

Annual accounts made up to 2024-09-30

9 months ago on 3 Jul 2025

Allotment of shares (GBP 7,444.53) on 2025-01-02

1 years ago on 6 Jan 2025

Termination of Michael Karim as director on 2024-09-30

1 years ago on 4 Oct 2024